OraQuick ADVANCE Rapid HIV-1/2 antibody test
Related Experiment Video
Updated: Aug 22, 2026
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Steven J Reynolds1, Jérémie Muwonga
1National Institute of Allergy and Infectious Diseases, National Institutes of Health, ICER Program Uganda, 2190 Kampala Place, Washington, DC 20521, USA. sjr@jhmi.edu
Abstract:
Rapid HIV antibody tests represent a key development in the current diagnosis and management of HIV infection. The OraQuick ADVANCE Rapid HIV-1/2 antibody test (OraSure Technologies) has received US Food and Drug Administration approval on the basis of its performance characteristics and a subsequent Clinical Laboratory Improvement Amendments waiver based on its simplicity and accuracy. The test has been approved for use on oral mucosal transudate, whole blood or plasma. Clinical evaluation of the OraQuick ADVANCE Rapid HIV-1/2 antibody test has revealed high sensitivity and specificity. The test has many important applications, extending the opportunities for voluntary counseling and testing, and as a tool for the scale-up of antiretroviral therapy in resource-limited settings.
